Soligenix

Clinical trials sponsored by Soligenix, explained in plain language.

Soligenix SNGX NASDAQ

A biopharmaceutical company developing treatments for rare diseases and biodefense.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 2 Terminated 1

Light-Activated gel shows promise for rare skin cancer

Disease control Stopped early

This Phase 3 trial tests a gel called HyBryte, which is activated by visible light, for treating cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. About 80 adults with early-stage CTCL will apply the gel or a placebo twice a week for 18 weeks, then receive light treat…

Phase 3 • Sponsor: Soligenix • Aim: Disease control

Last updated Jul 15, 2026 00:00 UTC

Soligenix

Light-Activated gel shows promise for rare skin cancer